1. Home
  2. ARTV vs SCLX Comparison

ARTV vs SCLX Comparison

Compare ARTV & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTV
  • SCLX
  • Stock Information
  • Founded
  • ARTV 2019
  • SCLX 2011
  • Country
  • ARTV United States
  • SCLX United States
  • Employees
  • ARTV N/A
  • SCLX N/A
  • Industry
  • ARTV
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARTV
  • SCLX Health Care
  • Exchange
  • ARTV NYSE
  • SCLX Nasdaq
  • Market Cap
  • ARTV 39.0M
  • SCLX 33.9M
  • IPO Year
  • ARTV 2024
  • SCLX N/A
  • Fundamental
  • Price
  • ARTV $1.61
  • SCLX $6.16
  • Analyst Decision
  • ARTV Strong Buy
  • SCLX Strong Buy
  • Analyst Count
  • ARTV 8
  • SCLX 3
  • Target Price
  • ARTV $18.14
  • SCLX $367.50
  • AVG Volume (30 Days)
  • ARTV 303.9K
  • SCLX 113.0K
  • Earning Date
  • ARTV 08-28-2025
  • SCLX 08-12-2025
  • Dividend Yield
  • ARTV N/A
  • SCLX N/A
  • EPS Growth
  • ARTV N/A
  • SCLX N/A
  • EPS
  • ARTV N/A
  • SCLX N/A
  • Revenue
  • ARTV N/A
  • SCLX $50,710,000.00
  • Revenue This Year
  • ARTV N/A
  • SCLX $107.00
  • Revenue Next Year
  • ARTV N/A
  • SCLX $82.52
  • P/E Ratio
  • ARTV N/A
  • SCLX N/A
  • Revenue Growth
  • ARTV N/A
  • SCLX 7.79
  • 52 Week Low
  • ARTV $1.47
  • SCLX $3.60
  • 52 Week High
  • ARTV $17.31
  • SCLX $78.05
  • Technical
  • Relative Strength Index (RSI)
  • ARTV N/A
  • SCLX 61.16
  • Support Level
  • ARTV N/A
  • SCLX $5.72
  • Resistance Level
  • ARTV N/A
  • SCLX $6.39
  • Average True Range (ATR)
  • ARTV 0.00
  • SCLX 0.42
  • MACD
  • ARTV 0.00
  • SCLX 0.13
  • Stochastic Oscillator
  • ARTV 0.00
  • SCLX 94.23

About ARTV ARTIVA BIOTHERAPEUTICS INC

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: